Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. - Cregg J; Edwards AV; Chang S; Lee BJ; Knox JE; Tomlinson ACA; Marquez A; Liu Y; Freilich R; Aay N; Wang Y; Jiang L; et al. (Journal of medicinal chemistry, 2025)